Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of resminostat alone and with sorafenib in advanced hepatocellular carcinoma progressing on sorafenib
2009-010760-42Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Resminostat and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by 4SC AG. Primary endpoints: Progression-free survival at 12 weeks and Maximum tolerated dose of resminostat in combination with sorafenib. Started Apr 2009; status: completed.
02
Drugs
Resminostatsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-010760-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010760-42.